Literature DB >> 6748943

Variable clinical and hormonal manifestations of hyperandrogenemia.

T J McKenna, T Loughlin, L Daly, P A Smyth, M Culliton, S K Cunningham.   

Abstract

This study was undertaken to contrast the hormonal profiles in patients with various hyperandrogenemic states in an attempt to correlate clinical manifestations with specific hormonal abnormalities. Patients with idiopathic hirsutism, polycystic ovaries, and a syndrome recently described by us, amenorrhea with cryptic hyperandrogenemia, ie, without hirsutism, participated. Total testosterone, the testosterone: sex-hormone-binding globulin (SHBG) ratio, and androstenedione levels were elevated in each group of patients. SHBG levels were suppressed in patients with idiopathic hirsutism and in patients with polycystic ovaries. In patients with polycystic ovaries or cryptic hyperandrogenemia, plasma estrone levels were elevated and the luteinizing hormone (LH) responses to luteinizing-hormone-releasing hormone (LH-RH) were exaggerated. Estrone is derived from androstenedione under the influence of the enzyme, aromatase. While elevated androstenedione occurred in both patients with polycystic ovaries or idiopathic hirsutism, estrone levels were only elevated in patients with polycystic ovaries. Reduced aromatase activity may have protected patients with idiopathic hirsutism from elevated estrone values and, thereby, from menstrual disturbances. The hormonal profiles in polycystic ovary syndrome and in patients with amenorrhea with cryptic hyperandrogenemia were very similar, with the exception that SHBG levels were high normal in three of five patients with cryptic hyperandrogenemia while estrone values were markedly elevated in these patients. Elevated estrone levels may explain the normal SHBG values, which are usually suppressed in hyperandrogenemic states. While each of the hyperandrogenemic disorders studied has a characteristic hormonal profile, the various clinical manifestations cannot be accounted for solely by abnormalities in circulating hormonal levels.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6748943     DOI: 10.1016/0026-0495(84)90210-5

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  3 in total

1.  High levels of testosterone inhibit ovarian follicle development by repressing the FSH signaling pathway.

Authors:  Tao Liu; Yu-Qian Cui; Han Zhao; Hong-Bin Liu; Shi-Dou Zhao; Yuan Gao; Xiao-Li Mu; Fei Gao; Zi-Jiang Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

2.  Common sex hormone abnormalities in women.

Authors:  T J McKenna
Journal:  Ir J Med Sci       Date:  1985-04       Impact factor: 1.568

3.  Plasma pro-opiomelanocortin fragments and adrenal steroids following administration of metyrapone to normal and hirsute women.

Authors:  S K Cunningham; T Loughlin; X Bertagna; F Girard; T J McKenna
Journal:  J Endocrinol Invest       Date:  1988-04       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.